- Home
- RLAY vs RERE Comparison
RLAY vs RERE Comparison
Compare RLAY & RERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- RERE
- Stock Information
- Founded
- RLAY 2015
- RERE 2011
- Country
- RLAY United States
- RERE China
- Employees
- RLAY N/A
- RERE N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- RERE Other Specialty Stores
- Sector
- RLAY Health Care
- RERE Consumer Discretionary
- Exchange
- RLAY Nasdaq
- RERE Nasdaq
- Market Cap
- RLAY 620.4M
- RERE 678.4M
- IPO Year
- RLAY 2020
- RERE 2021
- Fundamental
- Price
- RLAY $2.62
- RERE $2.96
- Analyst Decision
- RLAY Strong Buy
- RERE
- Analyst Count
- RLAY 10
- RERE 0
- Target Price
- RLAY $19.33
- RERE N/A
- AVG Volume (30 Days)
- RLAY 2.5M
- RERE 937.7K
- Earning Date
- RLAY 05-01-2025
- RERE 03-11-2025
- Dividend Yield
- RLAY N/A
- RERE N/A
- EPS Growth
- RLAY N/A
- RERE N/A
- EPS
- RLAY N/A
- RERE N/A
- Revenue
- RLAY $10,007,000.00
- RERE $2,237,042,920.00
- Revenue This Year
- RLAY N/A
- RERE $27.18
- Revenue Next Year
- RLAY $544.28
- RERE N/A
- P/E Ratio
- RLAY N/A
- RERE N/A
- Revenue Growth
- RLAY N/A
- RERE 25.93
- 52 Week Low
- RLAY $2.45
- RERE $1.50
- 52 Week High
- RLAY $10.72
- RERE $3.70
- Technical
- Relative Strength Index (RSI)
- RLAY 32.07
- RERE 44.54
- Support Level
- RLAY $3.05
- RERE $2.95
- Resistance Level
- RLAY $3.08
- RERE $3.24
- Average True Range (ATR)
- RLAY 0.25
- RERE 0.19
- MACD
- RLAY -0.04
- RERE -0.05
- Stochastic Oscillator
- RLAY 11.64
- RERE 14.62
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.